Our common stock trades on the NASDAQ under the symbol “ANIP.”
June 19, 2013
ANI has four locations including two U.S.-based manufacturing facilities and a facility in India. Our headquarters is located at:
500 Alexander Park
Princeton, New Jersey 08540
609-632-2776
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.
On June 19, 2013, pursuant to a merger agreement dated as of April 12, 2013, ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. ("ANIP") became a wholly-owned subsidiary of BioSante Pharmaceuticals, Inc. (“BioSante”) in an all-stock, tax-free reorganization (the "Merger"). The Merger was accounted for as a reverse acquisition, pursuant to which ANIP was considered the acquiring entity for accounting purposes. Since the Merger, we have been operating under the leadership of the ANIP management team and ANIP's historical results of operations have replaced BioSante's historical results of operations for all periods prior to the Merger. The results of operations of both companies are included in our consolidated financial statements for all periods after completion of the Merger. In July 2013, we changed our name from “BioSante Pharmaceuticals, Inc.” to “ANI Pharmaceuticals, Inc.”
Immediately prior to completion of the Merger, the Board of Directors authorized, declared and effected a distribution of contingent value rights (“CVRs”) to holders of record of Biosante Common Stock outstanding immediately prior to completion of the Merger at a rate of one CVR per one share of Common Stock. The CVRs represent payment rights arising from a future sale, transfer, license or similar transaction(s) involving the Company’s LibiGel® (female testosterone gel), including a royalty on sales of LibiGel® if the combined company launches the product on its own and if less than $2.5 million is spent on further product development before launch.
Iselin, New Jersey
No.
1 State Street, 30th Floor
New York, New York 10004-1561
Phone: 212-509-4000
Email: cstmail@continentalstock.com
Questions regarding stock transfer requirements, lost certificates and change of address should be directed to the transfer agent as listed.
No, ANI Pharmaceuticals does not offer a direct stock purchase plan. Shares can be purchased through a stockbroker of your choice.
December 31
ANI Pharmaceuticals’ Investor Relations department is happy to answer any shareholder questions at IR@anipharmaceuticals.com.
Requests for filings with the U.S Securities and Exchange Commission should be directed to Investor Relations at IR@anipharmaceuticals.com. SEC filings are also available on our website at www.anipharmaceuticals.com.